Bartosz Puła/LinkedIn
Oct 31, 2026, 10:54
Bartosz Puła: New Advances in Hematology Featured in Acta Haematologica Polonica
Bartosz Puła, Associate Professor at Medical University of Lodz, shared a post on LinkedIn:
“The new issue of Acta Haematologica Polonica is now available
As Editor-in-Chief, I invite you to explore Volume 57, Number 5. This issue brings together original Polish clinical research and focused reviews addressing targeted therapy, transplantation, CAR T-cell therapy, hemophilia, and the molecular biology of hematologic malignancies.
The issue includes:
- Preliminary report on prophylaxis with emicizumab in Polish infants with hemophilia A
Early Polish multicenter experience suggests fewer treated bleeding episodes, with no intracranial hemorrhage or adverse events reported during short-term follow-up. - The impact of proteinuria in allogeneic hematopoietic cell transplant recipients: a single center study employing urine protein electrophoresis
Proteinuria between days 8 and 21 after allo-HCT was associated with severe acute GvHD, supporting further evaluation of urinary protein electrophoresis. - Allogeneic stem cell transplantation remains an effective therapeutic option for patients with relapsed/refractory Hodgkin lymphoma: a Polish single-center retrospective analysis
In 24 patients, estimated two-year overall and progression-free survival both reached 83.3 percent, with acceptable toxicity. - Chimeric antigen receptor T-cell therapy in multiple myeloma in 2026: approved indications, long-term outcomes, toxicity, sequencing, and emerging platforms: a narrative review
A practice-oriented overview of approved BCMA-directed products, long-term outcomes, late toxicities, post-BCMA sequencing and emerging platforms. - Autophagy in myeloid neoplasms: what is there to discuss?
The review examines autophagy’s dual role in AML, MDS, and myeloproliferative neoplasms, including its contribution to treatment resistance. - Pirtobrutinib in the Bruton tyrosine kinase landscape in chronic lymphocytic leukemia: incremental advance or new standard?
A detailed assessment of pharmacology, clinical efficacy, safety, resistance and the evolving position of pirtobrutinib in CLL sequencing. - EZH2 mutations and their importance in hematologic disorders: from diagnostics to new treatment strategies
The authors connect molecular diagnostics and liquid biopsy with EZH2 inhibitors, dual EZH1/2 inhibition, PROTACs and gene-editing strategies. - Analysis of mechanisms increasing the risk of inhibitor development during hemophilia A treatment
A review of the genetic, immune and treatment-related determinants of factor VIII inhibitor formation and emerging therapeutic approaches. - A rare case of secondary cerebrospinal fluid involvement by extranodal marginal zone lymphoma of the salivary gland diagnosed in a paucicellular sample by flow cytometry
The report highlights the diagnostic value of flow cytometry when conventional CSF cytology is inconclusive.
Stay updated with Hemostasis Today.
-
Oct 31, 2026, 10:47Abhishek Kumar: Amplifying Patient Voices to Transform Haemophilia Care in Bihar
-
Oct 31, 2026, 10:42Josa Hanzlik: The Impact of Double Red Cell Donation
-
Oct 31, 2026, 09:10Alberto F. Chambi: Stroke and Cerebral Venous Thrombosis at High Altitude
-
Oct 31, 2026, 08:52Julianna Argueta: ATHN Data Summit – Advancing Collaboration in Blood Disorders
-
Oct 31, 2026, 08:11Paul Kariuki: Expanding Access to Plasma-Derived Medicines Across Africa
-
Oct 31, 2026, 07:09Akshay Sharma: Gene therapy for sickle cell disease
-
Oct 31, 2026, 07:00Owen McCarty: The Hidden Immune Mechanism Behind Chemotherapy-Associated Platelet Loss
-
Oct 31, 2026, 06:51Thijn Brummelkamp: SMIM1 Reveals a Novel Pathway for Cellular Iron Uptake Through Haemoglobin
-
Oct 31, 2026, 01:26Bringing the Voices of People With Bleeding Disorders to WHO Regional Discussions – World Federation of Hemophilia